News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Sequenom (SQNM) Intermune (ITMN) Xoma (XOMA) HALOZYME (HALO) Bristol-Myers Squibb (BMY) Agenus (AGEN) Rapamune Editas (EDIT) Velcade (bortezomib) Biocryst (BCRX) NANTKWEST (NK) Human Longevity (HLI) Adaptimmune (ADAP) Illumina (ILMN) Telaprevir Gilead (GILD) Dendreon (DNDN) GlaxoSmithKline (GSK) CompuGen (CGEN) ADVENTRIX (ANX) Onyx (ONXX) Biogen Idec (BIIB) Array Pharmaceuticals (ARRY) Ziofpharm (ZIOP) ImmunoGen (IMGN) Aimmune Therapeutics (AIMT) Endometrial Cancer galapagos (GLPG) BIOMARIN (BMRN) JUNO (JUNO) Jazz Pharmaceuticals (JAZZ) Benlysta (belimumab) Vitae Pharmaceuticals (VTAE) Mirati Therapeutics (MRTX) Bellicum (BLCM) Spike Therapeutics (ONCE) C4 Therapeutics OSI (OSIP) CEMPRA (CEMP) Inovio (INO) Revlimid (lenolidamide) Idenix (IDIX) Prolor Biotech (PBTH) Theravance (THRX) Sarepta (SRPT) SUNESIS PHARMACEUTICALS (SNSS) Pluristem (PSTI) ACADIA (ACAD) SERES THERAPEUTICS (MCRB) Roche (ROCHE) AERIE PHARMACEUTICALS Ridaforolimus Herceptin MODERNA Merck (MRK) Exelixis (EXEL) Zerenex Anacor (ANAC) RenenxBio (RGNX) NEKTAR (NKTR)) SYNTA (SNTA) CRISPR Therapeutics (CRSP) Tysabri Alnylam (ALNY) VANDA (VNDA) ABBVIE (ABBV) Micromet (MITI) Dynavax (DVAX) Intercept (ICPT) KITE (KITE) Vertex (VRTX) Roche (RHHBY) Incyte (INCY) Genentech Seattle Genetics (SGEN) Valeant Pharmaceuticals International (VRX) Advaxis (ADXS) Intrexon (XON) Ocular Therapeutix (OCUL) PTC Therapeutics (PTCT) ARGOS (ARGS) Sangamo (SGMO) Abbott Laboratories (ABT) Cytokinetics (CYTK) Prosensa (RNA) Trastuzumab-DM1 AstraZeneca (AZN) NOVOCURE (NVCR) Sanofi (SNY) TOKAI (TKAOI) AGOS (ARGS) Ionis (IONS) Global Cell Therapeutics (GBT) GUARDIAN HEALTH KERYX (KERX) REGULUS (RGLS) ARCA (ABIO) Regeneron (REGN) ISIS (ISIS) INNOVIVA (INVA) Alder Biopharmaceuticals (ALDR) Multiple Myeloma Auspex (ASPX) Sanofi-Aventis (SAN) ZALTRAP™ Human Genome Sciences (HGSI) Elan (ELN) Ariad (ARIA) Anadys (ANDS) Theravance Bio Pharma (TBPH) Sanofi (SNA) Galena (GALE) IDERA (IDRA) Agenus (AGEN Amgen (AMGN)